Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 95-101

  Vilahur, Gemma ^a,b   Casaní, Laura ^a,b   Peña, Esther ^a,b   Duran, Xavier ^a   Juan Babot, Oriol ^a   Badimon, Lina ^a,b,c  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Apoptosis; Heart function; Molecular biology; Myocardial infarction; RISK pathway

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE C; ROSUVASTATIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INDUCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; SWINE;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; DISEASE MODELS, ANIMAL; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SULFONAMIDES;

EID: 67650220186     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.02.009     Document Type: Article

References (32)

1. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1999;344:1383-9.
3. Ray K.K., and Cannon C.P. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol 15 (2004) 637-643
4. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
5. Jensen L.O., Thayssen P., Pedersen K.E., Stender S., and Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 110 (2004) 265-270
6. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
7. Massy Z.A., Keane W.F., and Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 347 (1996) 102-103
8. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
9. Casani L., Sanchez-Gomez S., Vilahur G., and Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 94 (2005) 1035-1041
10. Weitz-Schmidt G., Welzenbach K., Brinkmann V., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
11. Kivipelto M., Solomon A., and Winblad B. Statin therapy in Alzheimer's disease. Lancet Neurol 4 (2005) 521-522
12. Brouilette S.W., Moore J.S., McMahon A.D., et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369 (2007) 107-114
13. Lefer D.J., Scalia R., Jones S.P., et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15 (2001) 1454-1456
14. Bell R.M., and Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41 (2003) 508-515
15. Chen M.S., Xu F.P., Wang Y.Z., et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 37 (2004) 889-896
16. Rodriguez-Sinovas A., Abdallah Y., Piper H.M., and Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev 12 (2007) 207-216
17. Gottlieb R.A., Burleson K.O., Kloner R.A., Babior B.M., and Engler R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94 (1994) 1621-1628
18. Hausenloy D.J., and Yellon D.M. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35 (2003) 339-341
19. Hausenloy D.J., and Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12 (2007) 217-234
20. Jones S.P., Gibson M.F., Rimmer III D.M., et al. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
21. Di Napoli P., Taccardi A.A., Grilli A., et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 66 (2005) 462-471
22. Bulhak A.A., Gourine A.V., Gonon A.T., et al. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand 183 (2005) 151-159
23. Ibanez B., Prat-Gonzalez S., Speidl W.S., et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation 115 (2007) 2909-2916
24. Sharma R.K., Otsuka M., Pande V., Inoue J., and Joao Ramos M. Evans Blue is an inhibitor of nuclear factor-kappa B (NF-kappaB)-DNA binding. Bioorg Med Chem Lett 14 (2004) 6123-6127
25. Casani L., Segales E., Vilahur G., Bayes de Luna A., and Badimon L. Moderate daily intake of red wine inhibits mural thrombosis and monocyte tissue factor expression in an experimental porcine model. Circulation 110 (2004) 460-465
26. Brown J.H., Del Re D.P., and Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98 (2006) 730-742
27. Yaoita H., Ogawa K., Maehara K., and Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 97 (1998) 276-281
28. Bao N., Minatoguchi S., Kobayashi H., et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J 71 (2007) 1622-1628
29. Tiefenbacher C.P., Kapitza J., Dietz V., Lee C.H., and Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 285 (2003) H59-64
30. Liao J.K. Statin therapy for cardiac hypertrophy and heart failure. J Invest Med 52 (2004) 248-253
31. Zhao Z.Q., Velez D.A., Wang N.P., et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 6 (2001) 279-290
32. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209